Effect of Rifampin on Bosutinib When Both Are Given to Healthy People

Study to examine whether rifampin has an effect on the pharmacokinetics of bosutinib.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy men age 18-50
Healthy women of nonchildbearing potential, age 18-50

Treatment and study plan

Bosutinib

Drug

Primary outcomes

Pharmacokinetics (plasma concentrations)

Time frame: 4 weeks

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

A Study to Examine the Potential Effect of Rifampin on the Pharmacokinetics of Bosutinib When Administered Concomitantly to Healthy Subjects

Important dates

Study start: 2008
Primary completion: 2008
Study completion: 2008
First posted: Jul 30, 2008
Registry last updated: Apr 27, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed